Quantinno Capital Management LP Decreases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Quantinno Capital Management LP cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,417 shares of the company’s stock after selling 3,339 shares during the quarter. Quantinno Capital Management LP’s holdings in IDEXX Laboratories were worth $4,720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Sax Wealth Advisors LLC boosted its stake in shares of IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock valued at $590,000 after purchasing an additional 617 shares during the period. Hantz Financial Services Inc. raised its holdings in IDEXX Laboratories by 11.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after buying an additional 800 shares during the last quarter. Paragon Capital Management Inc. boosted its position in IDEXX Laboratories by 25.7% during the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company’s stock valued at $1,579,000 after buying an additional 782 shares during the period. Manitou Investment Management Ltd. grew its holdings in IDEXX Laboratories by 491.0% in the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company’s stock worth $21,582,000 after acquiring an additional 43,369 shares during the last quarter. Finally, Fiera Capital Corp increased its position in shares of IDEXX Laboratories by 12.3% in the fourth quarter. Fiera Capital Corp now owns 141,198 shares of the company’s stock valued at $58,377,000 after acquiring an additional 15,463 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research note on Monday, May 5th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $524.75.

IDEXX Laboratories Trading Up 1.2%

IDXX opened at $518.10 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $545.43. The stock has a market cap of $41.67 billion, a PE ratio of 48.56, a PEG ratio of 3.41 and a beta of 1.52. The business has a 50 day moving average of $431.28 and a 200-day moving average of $431.28.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.71 earnings per share. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.